Arena Pharmaceuticals’s partnership with Everest Medicines

Cooley advised Arena Pharmaceuticals on a development and commercialization partnership with Everest Medicines for two product candidates in mainland China, Taiwan, Hong Kong, Macau and South Korea.

The product candidates are ralinepag – for the treatment of pulmonary arterial hypertension – and etrasimod, which is being evaluated for multiple autoimmune diseases, including ulcerative colitis, a form of inflammatory bowel disease. C-Bridge Capital has invested $50 million to fund Everest and has assembled a veteran team to rapidly advance product candidates towards approval and launch.

Arena, which trades on The Nasdaq Global Select Market under the symbol “ARNA,” is a biopharmaceutical company focused on developing novel, small molecule drugs across a range of therapeutic areas. The company, led by Amit D Munshi, Kevin R Lind and

Vincent Aurentz, in 2016 recorded $124 Million Revenues.

Cooley partner Kay Chandler (Picture) and special counsel Rena Kaminsky lead the team advising Arena.

Involved fees earner: Kay Chandler – Cooley LLP; James Lu – Cooley LLP; Rena Kaminsky – Cooley LLP; Bin Wang – Cooley LLP; Jeremy Naylor – Cooley LLP;

Law Firms: Cooley LLP;

Clients: Arena Pharmaceuticals, Inc.;


Author: Michael Patrini